Skip to content

Burden of Respiratory Syncytial Virus (RSV) in the United Kingdom From 1995 to 2009

Burden of Respiratory Syncytial Virus (RSV) in the United Kingdom, 1995 to 2009

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01706302
Enrollment
1
Registered
2012-10-15
Start date
2012-10-31
Completion date
2012-11-30
Last updated
2013-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Syncyctial Virus Vaccines

Keywords

General Practice Research Database, Burden of Disease, Clinical Practice Research Datalink, Hospital Episode Statistics, Office of National Statistics, RSV

Brief summary

The study will assess the burden of RSV-attributable general practice consultations, hosptializations, and deaths by age and risk group in in United Kingdom from 1995 to 2009.

Detailed description

This epidemiological study is based on an already existing database of time series regression modeling outputs generated during the generated by EPI-FLU-018 BOD UK DB (116273) study, which estimated the burden of influenza in terms of General Practitioner (GP) consultations, hospitalizations, and deaths associated with various respiratory and non-respiratory outcomes.

Interventions

OTHERData collection

The previous study has used four primary data sources: the General Practice Research Data (GPRD \[recently re-named Clinical Practice Research Datalink (CPRD)\], for mild outcomes), the Hospital Episode Statistics database (HES, for hospitalizations), the Office of National Statistics mortality database (ONS, for mortality), and weekly virology data from the Health Protection Agency (HPA). The extracted data are referred to as the EPI-FLU-018 BOD UK DB database. Weekly time series will be generated to estimate the RSV burden and characterize it in terms of incidence of GP consultations, hospitalizations and deaths for each of the respiratory and non-respiratory outcomes (including GP antibiotic prescriptions), stratified by age and risk group.

Sponsors

Sage Analytica
CollaboratorINDUSTRY
GlaxoSmithKline
Lead SponsorINDUSTRY

Study design

Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

• Included in the EPI-FLU-018 BOD UK DB BOD UK DB (eTrack: 116273) study database. The inclusion criterion for EPI-FLU-018 was registration with an acceptable flag in the CPRD, or registration in the HES database or the ONS mortality data with a flu-related event.

Exclusion criteria

• Not Applicable

Design outcomes

Primary

MeasureTime frame
Occurrence in the EPI-FLU-018 BOD UK DB results database of potentially RSV-attributable GP consultation, hospitalization or death associated with respiratory outcomes.From 1995 to 2009

Secondary

MeasureTime frame
Occurrence in the EPI-FLU-018 BOD UK DB results database of potentially RSV-attributable GP consultation, hospitalization or death associated with non-respiratory outcomes.From 1995 to 2009
Occurrence in the EPI-FLU-018 BOD UK DB results database of potentially RSV-attributable GP prescription of antibiotics relevant to respiratory disease, by age and risk group.From 1995 to 2009
Peak occurrence of potentially RSV-attributable hospitalizations and deaths in elderly and pediatric populations.From 1995 to 2009
Occurrence of potentially RSV-attributable deaths among the total number of RSV-attributable hospitalizations and cases, by age and risk group.From 1995 to 2009

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 15, 2026